Oxford Cannabinoid drops on delayed clinical trials

Oxford Cannabinoid Technologies Holdings

26/08/2022 08:50

** Shares of Oxford Cannabinoid Technologies  OCTP.L  down
10.9% at 0.80p 
    ** The biopharmaceutical co temporarily delays Phase I
clinical trials of its second programme OCT130401  urn:newsml:reuters.com:*:nRSZ3472Xa
    ** Programme is aimed at developing medicine for faster
onset of pain relief, according to co website 
    ** However, co's Phase I clinical trials for its lead
programme remain on track and within budget
    ** Says existing co funds, which would otherwise have been
fully utilised by April 2023, will now extend until the last
quarter of 2023
    ** Co says group's chief finance director Karen Lowe will
step down from board 

    

 (Reporting by Prerna Bedi in Bengaluru)
 ((Prerna.Bedi@thomsonreuters.com;))